MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Levels of ferritinemia in Parkinson’s disease patients who underwent Covid-19

    B. Amonov, R. Matmurodov, B. Muminov (Tashkent, Uzbekistan)

    Objective: Comparison of serum IL-6 levels in Parkinson's disease (PD) patients with and without Сovid-19. Background: In the scientific literature, there is information about the…
  • 2024 International Congress

    Identifying Barriers and Facilitators to Accessing Care for Members of the Black Diaspora and Hispanic People Affected by Parkinson Disease: A Qualitative Study

    D. Kipnis, M. Lin, A. Pacheco, N. Mensah, Y. Gu, C. Macpherson, K. Kempner, A. Parker, RB. Coley, D. Coley, H. Shah, L. Quinn (New York, USA)

    Objective: To identify barriers and facilitators to care for members of the Black Diaspora (MBD) and Hispanic people affected by Parkinson Disease (PD). To identify…
  • 2024 International Congress

    Addressing Patient Needs: Enhancing Patient-Centered Care at the Movement Disorders Center

    M. Ivancic, A. Frohlich, W. Crutchfield, H. Morita, R. Murrow, J. Rider, D. Roque, M. Sklerov, C. Testa, J. Younce, N. Browner (Chapel Hill, USA)

    Objective: To define patients’ needs and enhance educational and quality improvement initiatives at our center. Background: Patient-centered care is critical for the managing the symptoms…
  • 2024 International Congress

    PD Young Ambassadors: A Peer-led, Community-Based Intervention to Raise PD Awareness in the Hispanic Communities of Chicago.

    J. Deliz, E. Espinoza, S. Kola, E. Zivin, K. Williams, J. Adrissi, P. Gonzalez-Latapi, D. Larson (Chicago, USA)

    Objective: To employ a community-based participatory research (CBPR) approach in developing and testing a workshop-based, peer-led intervention aimed at increasing PD awareness among youth and…
  • 2023 International Congress

    Opicapone’s Effects on Progression Scales in Relation to the 9-Symptom Wearing-off Questionnaire: the OPTIPARK Study

    D. Martins, A. Lees, H. Reichmann, J-F. Rocha (Coronado, Portugal)

    Objective: This study aims to evaluate changes in Parkinson’s disease (PD) progression scales in patients with PD and motor fluctuations (MF) treated with once-daily opicapone…
  • 2023 International Congress

    Long-term dementia prevalence in Parkinson disease: Glass half-full?

    J. Gallagher, J. Fedler, C. Gochanour, R. Dobkin, D. Aarsland, R. Alcalay, M. Barrett, C. Caspell-Garcia, R. Cho, L. Chahine, A. Chen-Plotkin, C. Coffey, N. Dahodwala, J. Eberling, A. Espay, J. Leverenz, I. Litvan, E. Mamikonyan, J. Morley, I. Richard, L. Rosenthal, A. Siderowf, T. Simuni, M. York, A. Willis, S. Xie, D. Weintraub (Philadelphia, USA)

    Objective: To determine long-term, cumulative dementia prevalence rates in Parkinson disease (PD) using data from two large, ongoing, prospective observational studies. Background: Dementia is reported to occur in…
  • 2023 International Congress

    Brain MRI volumetry analysis for patients with Parkinson’s disease suffering from REM sleep behavior disorder: a pilot study

    T. Vanagas, G. Paulekiene, A. Radziunas, R. Balnyte, E. Pajediene, E. Paulekas (Kaunas, Lithuania)

    Objective: To detect patients with Parkinson's disease that have REM sleep behavior disorder (RBD) and perform brain MRI volumetry analysis. Background: Parkinson’s disease is classically…
  • 2023 International Congress

    Frequency of Parkinson disease following COVID-19 infection: a two-year retrospective cohort study

    A. Wang, J. Perez, S. Gunzler (Cleveland, USA)

    Objective: We aimed to utilize a large healthcare research network to determine the risk of developing Parkinson disease following COVID-19 infection compared individuals without COVID-19…
  • 2023 International Congress

    Impact of dopamine replacement therapy on shame in Parkinson’s disease patients

    S. Catalano Chiuvé, D. Benis, A. Zulet, P. Krack, V. Fleury (Geneva, Switzerland)

    Objective: This study aims to investigate the effect of dopaminergic replacement therapy (DRT) on shame using emotional dynamic rating scales during ON and OFF-DRT states.…
  • 2023 International Congress

    Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson’s disease.The AMBITIOUS Study Protocol

    F. Colucci, M. Avenali, R. de Micco, A. Bacila, S. Cerri, G. Cuconato, V. Franco, D. Franciotta, C. Ghezzi, M. Gastaldi, C. Galandra, G. Germani, P. Mitrotti, G. Ongari, I. Palmieri, M. Picascia, A. Pichiecchio, F. Esposito, M. Cirillo, F. Di Nardo, S. Aloisio, M. Siciliano, M. Fusar Poli, M. Stanziano, B. Garavaglia, F. Cazzaniga, C. Reale, I. Tramacere, S. Priori, P. Amami, S. Piacentini, MG. Bruzzone, M. Grisoli, F. Moda, R. Eleopra, A. Tessitore, EM. Valente, R. Cilia (Milan, Italy)

    Objective: To determine in Parkinson’s disease (PD) patients carrying GBA mutation the role of Ambroxol (ABX) on the progression of cognitive performance (primary aim), motor…
  • « Previous Page
  • 1
  • …
  • 190
  • 191
  • 192
  • 193
  • 194
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Comorbid Normal Pressure Hydrocephalus with Parkinson’s disease: a call for clinical awareness
  • Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome
  • Common mistakes in the MoCA test in patients with Parkinson’s Disease in Kyrgyzstan
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley